AVANIR PHARMACEUTICALS WILL HOST A CONFERENCE CALL TO DISCUSS THE RECENT FDA ANNOUNCEMENT ON NEURODEX, TODAY JUNE 20, 2006
San Diego, June 20, 2006 – Avanir Pharmaceuticals (NASDAQ: AVNR) will host a conference call on June 20, 2006 at 1:00 P.M. PST to discuss the U.S. Food and Drug Administration's recent decision to extend the PDUFA date on the Company's Neurodex™ NDA by 90 days. The call will be webcast live through Avanir's corporate website at www.avanir.com and will feature Eric Brandt, President and Chief Executive Officer, and Randall Kaye, M.D., Vice President of Medical Affairs. A press release announcing the FDA's decision was issued on June 19, 2006 and is available from the Company's website.
It is recommended that you go to Avanir's website at least 10 minutes in advance of the webcast to download any applicable software. For those who cannot listen to the live broadcast, the online replay will be available for 30 days, and a phone replay will be available through June 27, 2006, by dialing 800-642-1687 (domestic) and 706-645-9291 (international) and entering the passcode 2061879.
Avanir Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. Avanir currently markets FazaClo®, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder. For full prescribing information and important safety information regarding FazaClo, please visit www.fazaclo.com Avanir's lead product candidate, Neurodex™ for the treatment of involuntary emotional expression disorder, is the subject of a New Drug Application under priority review with the FDA. Additionally, Avanir has initiated a Phase III clinical trial with Neurodex as a potential treatment for patients with painful diabetic neuropathy. Avanir has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease. The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about Avanir can be found at www.avanir.com.
Avanir Pharmaceuticals Contacts:
|What do you think?|
|Jun 20, 2006|